Precigen
Precigen Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative gene and cellular therapies utilizing its proprietary precision technology platforms to treat infectious diseases, autoimmune disorders, and cancers. The company develops novel non-viral gene transfer technologies, synthetic biology solutions, and therapeutic cell constructs designed to precisely target and eliminate diseased cells. Its core business operations encompass biopharmaceutical research, genetic engineering, clinical trial execution, and pharmaceutical product development. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through public equity offerings and strategic research collaborations. Precigen holds a pioneering market position in synthetic biology and gene therapy. The company is headquartered in Germantown, Maryland, United States, and its common stock trades on the Nasdaq Global Market.
3 of the funds FundTelligence covers report a position in Precigen.
- Legal name
- PRECIGEN
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Precigen
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)